Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Revvity (RVTY) is 5/10.
Revvity reported Q1 adjusted EPS of $1.06 with 3% organic growth, while announcing the strategic divestiture of the China immunodiagnostics business. Pro forma excluding China IDx, organic growth was 6%, and life sciences instruments grew mid-single digits for the strongest quarter since early 2023. Academic and government customers returned to growth with US positive for the first time since Q2 2023. EPS guidance was recast to $5.20-$5.30 pro forma, reflecting the divestiture removal.
Scored from Revvity’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $729M | +4.8% | $0.78 | -6.3% | 49.3% | 18.1% | 13.0% | $150M |
| FY2025 Q1 | $665M | +2.3% | $0.34 | +53.6% | 56.5% | 10.9% | 6.4% | $112M |
| FY2025 Q2 | $720M | +4.1% | $0.47 | -26.6% | 54.5% | 12.6% | 7.7% | $115M |
| FY2025 Q3 | $699M | +2.2% | $0.40 | -47.6% | 53.6% | 11.7% | 6.7% | $120M |
| FY2025 Q4 | $772M | +5.9% | $0.87 | +11.5% | 43.8% | 14.5% | 12.7% | $163M |
| FY2026 Q1 | $711M | +7.0% | $0.36 | +4.5% | 54.5% | 10.7% | 5.7% | $95M |
| FY2026 Q2 | $730M | +1.3% | $0.47 | 0.0% | 57.1% | 12.2% | 7.1% | $184M |
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.